Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Solid Biosciences Inc. Director's Dealing 2026

Feb 2, 2026

33003_dirs_2026-02-02_b4f3db38-1b93-4500-822b-987b398a456a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Solid Biosciences Inc. (SLDB)
CIK: 0001707502
Period of Report: 2026-01-29

Reporting Person: Tan Kevin (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-01-29 Common Stock M 56646 Acquired 102746 Direct
2026-01-31 Common Stock M 33075 Acquired 135821 Direct
2026-02-02 Common Stock S 26837 $6.4369 Disposed 108984 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-01-29 Performance Stock Units $ M 56646 Disposed Common Stock (56646) Direct
2026-01-29 Employee Stock Option (Right to Buy) $6.60 A 187000 Acquired 2036-01-29 Common Stock (187000) Direct
2026-01-29 Restricted Stock Units $ A 93500 Acquired Common Stock (93500) Direct
2026-01-31 Restricted Stock Units $ M 33075 Disposed Common Stock (33075) Direct

Footnotes

F1: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

F2: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F3: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

F5: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

F6: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

F7: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

F8: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 132,300 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.